Cargando…

Current State of “Omics” Biomarkers in Pancreatic Cancer

Pancreatic cancer is one of the most fatal malignancies and the seventh leading cause of cancer-related deaths related to late diagnosis, poor survival rates, and high incidence of metastasis. Unfortunately, pancreatic cancer is predicted to become the third leading cause of cancer deaths in the fut...

Descripción completa

Detalles Bibliográficos
Autores principales: Turanli, Beste, Yildirim, Esra, Gulfidan, Gizem, Arga, Kazim Yalcin, Sinha, Raghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918884/
https://www.ncbi.nlm.nih.gov/pubmed/33672926
http://dx.doi.org/10.3390/jpm11020127
_version_ 1783658024400846848
author Turanli, Beste
Yildirim, Esra
Gulfidan, Gizem
Arga, Kazim Yalcin
Sinha, Raghu
author_facet Turanli, Beste
Yildirim, Esra
Gulfidan, Gizem
Arga, Kazim Yalcin
Sinha, Raghu
author_sort Turanli, Beste
collection PubMed
description Pancreatic cancer is one of the most fatal malignancies and the seventh leading cause of cancer-related deaths related to late diagnosis, poor survival rates, and high incidence of metastasis. Unfortunately, pancreatic cancer is predicted to become the third leading cause of cancer deaths in the future. Therefore, diagnosis at the early stages of pancreatic cancer for initial diagnosis or postoperative recurrence is a great challenge, as well as predicting prognosis precisely in the context of biomarker discovery. From the personalized medicine perspective, the lack of molecular biomarkers for patient selection confines tailored therapy options, including selecting drugs and their doses or even diet. Currently, there is no standardized pancreatic cancer screening strategy using molecular biomarkers, but CA19-9 is the most well known marker for the detection of pancreatic cancer. In contrast, recent innovations in high-throughput techniques have enabled the discovery of specific biomarkers of cancers using genomics, transcriptomics, proteomics, metabolomics, glycomics, and metagenomics. Panels combining CA19-9 with other novel biomarkers from different “omics” levels might represent an ideal strategy for the early detection of pancreatic cancer. The systems biology approach may shed a light on biomarker identification of pancreatic cancer by integrating multi-omics approaches. In this review, we provide background information on the current state of pancreatic cancer biomarkers from multi-omics stages. Furthermore, we conclude this review on how multi-omics data may reveal new biomarkers to be used for personalized medicine in the future.
format Online
Article
Text
id pubmed-7918884
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79188842021-03-02 Current State of “Omics” Biomarkers in Pancreatic Cancer Turanli, Beste Yildirim, Esra Gulfidan, Gizem Arga, Kazim Yalcin Sinha, Raghu J Pers Med Review Pancreatic cancer is one of the most fatal malignancies and the seventh leading cause of cancer-related deaths related to late diagnosis, poor survival rates, and high incidence of metastasis. Unfortunately, pancreatic cancer is predicted to become the third leading cause of cancer deaths in the future. Therefore, diagnosis at the early stages of pancreatic cancer for initial diagnosis or postoperative recurrence is a great challenge, as well as predicting prognosis precisely in the context of biomarker discovery. From the personalized medicine perspective, the lack of molecular biomarkers for patient selection confines tailored therapy options, including selecting drugs and their doses or even diet. Currently, there is no standardized pancreatic cancer screening strategy using molecular biomarkers, but CA19-9 is the most well known marker for the detection of pancreatic cancer. In contrast, recent innovations in high-throughput techniques have enabled the discovery of specific biomarkers of cancers using genomics, transcriptomics, proteomics, metabolomics, glycomics, and metagenomics. Panels combining CA19-9 with other novel biomarkers from different “omics” levels might represent an ideal strategy for the early detection of pancreatic cancer. The systems biology approach may shed a light on biomarker identification of pancreatic cancer by integrating multi-omics approaches. In this review, we provide background information on the current state of pancreatic cancer biomarkers from multi-omics stages. Furthermore, we conclude this review on how multi-omics data may reveal new biomarkers to be used for personalized medicine in the future. MDPI 2021-02-14 /pmc/articles/PMC7918884/ /pubmed/33672926 http://dx.doi.org/10.3390/jpm11020127 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Turanli, Beste
Yildirim, Esra
Gulfidan, Gizem
Arga, Kazim Yalcin
Sinha, Raghu
Current State of “Omics” Biomarkers in Pancreatic Cancer
title Current State of “Omics” Biomarkers in Pancreatic Cancer
title_full Current State of “Omics” Biomarkers in Pancreatic Cancer
title_fullStr Current State of “Omics” Biomarkers in Pancreatic Cancer
title_full_unstemmed Current State of “Omics” Biomarkers in Pancreatic Cancer
title_short Current State of “Omics” Biomarkers in Pancreatic Cancer
title_sort current state of “omics” biomarkers in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918884/
https://www.ncbi.nlm.nih.gov/pubmed/33672926
http://dx.doi.org/10.3390/jpm11020127
work_keys_str_mv AT turanlibeste currentstateofomicsbiomarkersinpancreaticcancer
AT yildirimesra currentstateofomicsbiomarkersinpancreaticcancer
AT gulfidangizem currentstateofomicsbiomarkersinpancreaticcancer
AT argakazimyalcin currentstateofomicsbiomarkersinpancreaticcancer
AT sinharaghu currentstateofomicsbiomarkersinpancreaticcancer